Prellis Biologics
PrivateLast Round
Series C
Aug 10, 2022
Total Funding Raised
$64.55M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Prellis Biologics operates in Healthcare & Life Sciences and is based in Berkeley, California. Its latest recorded funding round was a Series C round in August 2022.
Prellis Biologics is a biotechnology company that specializes in advanced bioprinting technology to engineer human tissues in vitro, enabling precise reproduction of the human immune response for applications such as antibody discovery and tumor-immune modeling.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, 3D Printing, Biotech Equipment
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Prellis Biologics Comparables
Compare Prellis Biologics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Inventia Life Science | 80% | |
| Adimab | 79% | |
| AlivaMab Biologics | 79% |
For institutional investors. Book with your work email.
Prellis Biologics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 10, 2022 | ||||
| Series B | Dec 14, 2021 | ||||
| Series A Extension | May 19, 2020 | ||||
| Series A | Jul 29, 2019 | ||||
| Seed | Sep 14, 2017 | ||||
Accelerator | May 31, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Prellis Biologics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Future Ventures | Series A Extension |
| 415 Ventures | Seed |
| Khosla Ventures | Series C, Series A Extension, Series A, Series B |
| WRVI Capital | Series C, Series B |
| Avidity Partners | Series C |
| Celesta Capital | Series C, Series B |
| IndieBio | Series A Extension, Series A, Seed, Series B, Accelerator |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 93% MoM.
- Mar 24, 2026
Developing programs in obesity, inflammation/immunology, and oncology.
For institutional investors. Book with your work email.
Prellis Biologics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Prellis Biologics's valuation, stock price, and market status.
Is Prellis Biologics a public or private company?
Prellis Biologics is a private company.
What is the current stock price of Prellis Biologics?
Prellis Biologics is a private company, so its shares have no public market price. Caplight tracks Prellis Biologics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Prellis Biologics worth (valuation)?
Valuation information for Prellis Biologics is not publicly available.
Can I buy Prellis Biologics stock?
Prellis Biologics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Prellis Biologics's last funding round?
Prellis Biologics's most recent funding round was Series C on August 10, 2022.
Who are the main investors in Prellis Biologics?
Key investors in Prellis Biologics include Future Ventures, Khosla Ventures, WRVI Capital, Avidity Partners, Celesta Capital.
Will Prellis Biologics IPO soon?
No public IPO plans have been announced for Prellis Biologics.
How can I track Prellis Biologics secondary market activity?
Caplight tracks bids, offers, and trades in Prellis Biologics's shares on secondary markets.